PASW
Ping An Biomedical Co., Ltd. (PASW) Risks & Opportunities Analysis (2026)
No material changes this month.
Risks
Negative net debt to EBITDA and strong liquidity reduce refinancing pressure versus leveraged peers, limiting balance-sheet risk even if operating volatility persists.
Very high days sales outstanding lengthen cash collection versus faster-turning peers, which can constrain working-capital conversion and temper near-term cash generation.
A long cash conversion cycle versus more efficient peers can delay cash realization, making growth less self-funding if demand expands faster than collections.
Interest coverage is distorted by negative EBITDA, but the low debt load versus peers still suggests financing risk is manageable unless earnings remain weak.
Inventory days are low versus many distributors, which cushions obsolescence risk and partially offsets the working-capital drag from slower receivables collection.
Opportunities
Net cash positioning versus more levered peers provides flexibility to support growth, absorb volatility, and preserve strategic optionality in a tighter credit environment.
Strong current and quick ratios versus peers indicate ample near-term liquidity, supporting customer service and procurement continuity when working capital needs rise.
Low inventory days versus peers suggest disciplined stock management, which can improve cash efficiency and reduce markdown risk as demand normalizes.
If receivables collection improves toward peer levels, cash conversion could strengthen materially, unlocking better free-cash-flow conversion than slower-turning competitors.
Modest debt-to-equity versus peers leaves room to fund selective expansion without materially increasing balance-sheet strain, supporting relative positioning over the next 1–5 years.
Overall Score
PASW’s net-cash balance sheet and strong liquidity support resilience versus peers, while elevated receivables and a long cash conversion cycle remain the main constraints on cash realization.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Ping An Biomedical Co., Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
